US Stock MarketDetailed Quotes
GNPX Genprex
- 1.1000
- -0.0400-3.51%
Close Nov 22 16:00 ET
- 1.1100
- +0.0100+0.91%
Post 20:02 ET
9.36MMarket Cap-102P/E (TTM)
1.2000High1.0800Low573.87KVolume1.1500Open1.1400Pre Close658.74KTurnover6.75%Turnover RatioLossP/E (Static)8.51MShares14.400052wk High5.61P/B9.35MFloat Cap0.280652wk Low--Dividend TTM8.50MShs Float778.0000Historical High--Div YieldTTM10.53%Amplitude0.2800Historical Low1.1470Avg Price1Lot Size
About Genprex Company
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
Company Profile
SymbolGNPX
Company NameGenprex
Listing DateMar 29, 2018
Issue Price5.00
Founded2009
CEOMr. Ryan M. Confer
MarketNASDAQ
Employees26
Fiscal Year Ends12-31
Address3300 Bee Cave Road,Suite 650-227
CityAustin
ProvinceTexas
CountryUnited States of America
Zip Code78746
Phone1-877-774-4679
Websitehttp://www.genprex.com
Company Executives
- Name
- Position
- Salary
- Ryan M. Confer
- Director, President, Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer
- --
- Dr. Mark S. Berger, M.D.
- Chief Medical Officer
- 947.11K
- Brent Longnecker
- Independent Director
- 161.61K
- William R. Wilson, Jr
- Independent Director
- 151.16K
- Jose Antonio Moreno Toscano
- Independent Director
- 161.61K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data